Reblozyl – TIF
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial - The Lancet Haematology
MEDALIST: Luspatercept in MDS - Capsule Summary Slidesets - MDS and MPNs - 2019 ASH Annual Meeting - Oncology - Clinical Care Options
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes | NEJM
Selected novel agents in clinical trials for lower-risk MDS Several... | Download Scientific Diagram
Development of luspatercept to treat ineffective erythropoiesis - ScienceDirect
Reblozyl® (luspatercept-aamt) MEDALIST Trial Details | MDS-RS
REBLOZYL® for Treatment of Anaemia Associated with Beta-Thalassemia
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia | NEJM
Phase 3 Trial of Luspatercept for Transfusion-Dependent β-Thalassemia | NEJM
Acceleron And Celgene Deliver Strong Results In The Phase 3 MEDALIST Trial (NASDAQ:CELG) | Seeking Alpha
Luspatercept for Myelodysplastic Syndromes Clinical Trial 2022 | Power
Current ongoing clinical trials using luspatercept. | Download Scientific Diagram
Document
Current ongoing clinical trials using luspatercept. | Download Scientific Diagram
Acceleron And Celgene Deliver Strong Results In The Phase 3 MEDALIST Trial (NASDAQ:CELG) | Seeking Alpha
MEDALIST: Luspatercept in MDS - Capsule Summary Slidesets - MDS and MPNs - 2019 ASH Annual Meeting - Oncology - Clinical Care Options
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study - The Lancet Oncology
Luspatercept: First Approval | SpringerLink
Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes - Chen - 2020 - CPT: Pharmacometrics & Systems Pharmacology - Wiley Online Library
EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS PLACEBO IN PATIENTS WITH.... EHA Library. Mesa R. Jun 9 2021; 324375
Acceleron: Luspatercept New Data Is A Buy Signal (NYSE:MRK) | Seeking Alpha
Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia. - Abstract - Europe PMC
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study - The Lancet Oncology
Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes | Leukemia
